# The Francis Crick Institute

> The Francis Crick Institute is a VC fund backing Health Care and Biotechnology. See 9 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 9
- Last investment: Jul 2026
- Lead investor: 22%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/the-francis-crick-institute?trk=tyah&trkInfo=tarId%3A1414765472532%2Ctas%3Afrancis+crick%2Cidx%3A2-1-5
- X (Twitter): https://twitter.com/thecrick
- Website: http://crick.ac.uk/
- Facebook: https://www.facebook.com/TheFrancisCrickInstitute

The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. Its work is helping to understand why disease develops and to find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.By bringingtogether scientists from many disciplines, the Crick will help to improve people's lives and keep the UK at the forefront of innovation in medical research, attracting high-value investment and strengthening the economy.

## Contacts

5 contacts available for The Francis Crick Institute. Shizune tracks 3 team members at The Francis Crick Institute. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/the-francis-crick-institute?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 67% |
| Biotechnology | 5 | 56% |
| Health Diagnostics | 4 | 44% |
| Medical | 3 | 33% |
| Therapeutics | 3 | 33% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 67% |
| Pre-Seed | 1 | 11% |
| Series B | 1 | 11% |
| Convertible Note | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Simon Bayly | Senior Business Manager -Translation | 0 | — |
| Dan Fitz | General Counsel & Company Secretary | 0 | — |
| Jim Smith | Group Leader | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Respiro Diagnostics | Respiro Diagnostics develops non-invasive breath-based diagnostic tests focused on respiratory and oncology applications. The company builds a breath-based diagnostic platform that combines a proprietary collection device with molecular laboratory analysis to capture extracellular vesicles and other lung-derived biomarkers from exhaled breath. Itsinitial applications target earlier and more accurate detection of lung cancer and mesothelioma, with extension to other respiratory conditions and cancer research. Clinicians collect breath samples in minutes using the Respiro device and send them to the Respiro lab for high-resolution molecular profiling. The resulting reports are provided back to clinicians to support screening decisions, referrals, and treatment planning. Respiro Diagnostics also supports drug development and clinical research by generating rich molecular data from the lungs for use in studies and experimental therapies. | $1.3M | Pre-Seed | Jul 08, 2026 |  |
| PulseAI | PulseAI is an medical technology startup that uses AI to detection heart disease. |  | Seed | Jan 12, 2026 |  |
| LinkGevity | LinkGevity is an drug discovery company that focuses on life span and diseases associated with aging. |  | Seed | Jan 22, 2025 |  |
| EnhancedDx | EnhancedDx unblocks each stage of the patient pathway and helps clinicians make decisions most likely to result in positive outcome We reduce the time to treatment from 3 years to 30 days with at-home testing, remote diagnostics, and AI-enabled care. To learn more, please visit our website. | $50.1K | Convertible Note | Jan 01, 2025 |  |
| Siloton | Siloton is a medical device manufacturing company that designs and develops diagnostic imaging devices in the field of ophthalmology. | $1.1M | Seed | Oct 14, 2024 |  |
| Enara Bio | Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences. | $32.5M | Series B | Oct 03, 2024 |  |
| OxCan | OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection. | $1.8M | Seed | Sep 06, 2021 |  |
| Achilles Therapeutics | Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enablingscientists to target and destroy tumors without harming healthy tissues. | $16.8M | Seed | Sep 28, 2016 |  |
| GammaDelta Therapeutics | GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy. |  | Seed | Sep 16, 2016 |  |

9 of 9 investments shown.

## Co-investors
- [Cancer Research Horizons](https://shizune.co/investors/profile/cancer-research-technology) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [AlbionVC](https://shizune.co/investors/profile/albion-vc) — VC Fund, 1 deal together
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 1 deal together
- Cancer Research UK — VC Fund, 1 deal together
- [Civilization Ventures](https://shizune.co/investors/profile/civilization-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does The Francis Crick Institute invest in?

The Francis Crick Institute invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact The Francis Crick Institute?

Public channels for The Francis Crick Institute include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at The Francis Crick Institute?

The team at The Francis Crick Institute includes Simon Bayly (Senior Business Manager -Translation), Dan Fitz (General Counsel & Company Secretary) and Jim Smith (Group Leader). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co